Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation

Category	Detail
Condition	Myocardial Infarction (MI)
Key Mechanisms	Bidirectional crosstalk between the injured heart and immune organs, involving cytokine networks and macrophage polarization.
Target Population	Middle-aged and elderly populations, patients with underlying cardiac conditions or high-risk factors (e.g., smoking, diabetes, hyperlipidemia).
Care Setting	Acute care settings, including emergency departments and cardiac care units.

MI triggers a systemic immune response with complex inter-organ communication.
The post-MI immune response is divided into three phases: inflammation, resolution, and remodeling.
Targeting specific immune mechanisms may preserve cardiac function and improve long-term outcomes.
Emerging immunomodulatory strategies focus on macrophage polarization and regulatory T cell promotion.
Current therapies include antiplatelet agents, anticoagulants, and revascularization procedures.

Rapid assessment of coronary artery occlusion through clinical evaluation and imaging.

Immediate restoration of coronary blood flow using pharmacological interventions and revascularization.

Continuous monitoring for signs of ischemia-reperfusion injury and systemic inflammation.

Patients experiencing acute myocardial infarction.

Combination of dual antiplatelet therapy and revascularization is critical for acute management.

Implement phase-specific strategies for managing the immune response post-MI.
Consider the timing and dosage of immunomodulatory therapies to optimize patient outcomes.
Engage in multidisciplinary approaches to address comorbidities affecting MI recovery.

Clinical Scorecard: Modulating the Heart-Immune Interaction Following Myocardial Infarction: From Inflammatory Response to Immune Regulation